Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02678585

Enrollment

106

Registered

2016-02-10

Start date

2015-12-31

Completion date

2016-03-31

Last updated

2018-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

The effect of addition of nalbuphine to lidocaine in intravenous regional anesthesia

Interventions

DRUGNalbuphine

53 patients received intravenous regional lidocaine plus nalbuphine

DRUGLidocaine

53 patients received intravenous regional lidocaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* adult patients * American Society of Anesthesiologists (ASA) physical status I-II * age between 20 and 50 years old * scheduled for elective unilateral short hand surgery

Exclusion criteria

* allergy to study medications * body mass index \> 35 kg/m2 * patients with sickle cell disease or Reynaud disease * patient refusal

Design outcomes

Primary

Measure	Time frame
Tourniquet and postoperative pain measured by visual analogue scale	4 hours

Secondary

Measure	Time frame
Cortisol level	4 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026